Bernstein Clinical Research Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$133,621	54
2024	Research	$93,822	60
2023	Research	$98,357	27
2022	Research	$149,221	63
2021	Research	$162,238	40
2020	Research	$85,654	6
2019	Research	$199,828	13

Breakdown

Who paid Research payments · program years 2019–2025

CSL Behring $477,978 215 payments
Novartis Pharmaceuticals Corporation $272,030 22 payments
Cipla USA Inc. $111,405 7 payments
Regeneron Pharmaceuticals, Inc. $58,137 17 payments
Takeda Pharmaceuticals U.S.A., Inc. $3,190 2 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $175,824 47 payments
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $167,436 93 payments
U-Fs-Mu-As3120 $111,405 7 payments
A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $83,228 2 payments
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age $77,614 46 payments
A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home $52,137 15 payments
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $50,133 1 payment
A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $50,039 4 payments
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age $40,239 20 payments
A Multi-Center, Double-Blinded and Open-Label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge03 $24,216 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.